LAMICTAL ODT

Compare LAMICTAL ODT  to:
Compare
Compare

Generic Name for LAMICTAL ODT

Lamotrigine 25mg, 50mg, 100mg, and 200mg; orally-disintegrating tabs.

Legal Classification:

Rx

Pharmacological Class for LAMICTAL ODT

Phenyltriazine.

Manufacturer of LAMICTAL ODT

GlaxoSmithKline Pharmaceuticals

Indications for LAMICTAL ODT

Adjunct in partial seizures, Lennox-Gastaut syndrome, or primary generalized tonic-clonic seizures in adults and children (≥2yrs). Conversion to monotherapy in adults (≥16yrs) with partial seizures who are on carbamazepine, phenytoin, phenobarbital, primidone, or valproate as a single antiepileptic drug (AED).

Adult dose for LAMICTAL ODT

Chew tabs: give only whole tabs, round dose down to nearest whole tab (may be swallowed whole, chewed, or mixed in water or diluted fruit juice). ODT: dissolve on tongue and swallow with or without water. Adding to antiepileptic drug (AED) regimens that include valproate: initially 25mg every other day for 2 weeks, then 25mg once daily for 2 weeks; may increase by 25–50mg/day at 1–2 week intervals; usual maintenance 100–400mg/day in 1 or 2 divided doses. Adding to valproate only: usual maintenance 100–200mg/day. Adding to AED regimens other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate: initially 25mg once daily for 2 weeks; then 50mg once daily for 2 weeks; may increase by 50mg/day at 1–2 week intervals; usual maintenance 225–375mg/day in 2 divided doses. Adding to AED regimens without valproate: initially 50mg per day for 2 weeks, then 100mg daily in 2 divided doses for 2 weeks; may increase by 100mg/day at 1–2 week intervals; usual maintenance 300–500mg/day in 2 divided doses. Converting from one AED (not valproate) to lamotrigine monotherapy (first titrate lamotrigine, then withdraw AED): initially 50mg per day for 2 weeks, then 100mg daily in 2 divided doses for 2 weeks; may increase by 100mg/day at 1–2 week intervals to 500mg/day in 2 divided doses. Then reduce AED dose by 20% per week for 4 wks. Converting from valproate to lamotrigine monotherapy: see literature. Concomitant estrogen-containing oral contraceptives or hormone replacement therapy: see literature. Hepatic impairment: if moderate or severe (w/o ascites) reduce dose by 25%; if severe (w. ascites) reduce dose by 50%.

Children's dosing for LAMICTAL ODT

Chew tabs: give only whole tabs, round dose down to nearest whole tab (may be swallowed whole, chewed, or mixed in water or diluted fruit juice). ODT: dissolve on tongue and swallow with or without water. <2yrs: not recommended. 2–12yrs: Adding to AED regimens that include valproate: initially 0.15mg/kg per day in 1 or 2 divided doses for 2 weeks, then 0.3mg/kg per day in 1 or 2 divided doses for 2 weeks; may increase by 0.3mg/kg per day at 1–2 week intervals in 1 or 2 divided doses; usual maintenance 1–5mg/kg per day; max 200mg/day in 1 or 2 divided doses. Adding to valproate only: usual maintenance 1–3mg/kg per day. Adding to AED regimens other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate: initially 0.3mg/kg per day in 1 or 2 divided doses for 2 weeks, then 0.6mg/kg per day in 2 divided doses for 2 weeks; may increase by 0.6mg/kg per day at 1–2 week intervals; usual maintenance 4.5–7.5mg/kg per day; max 300mg/day in 2 divided doses. Adding to AED regimens without valproate: initially 0.6mg/kg per day in 2 divided doses for 2 weeks, then 1.2mg/kg per day in 2 divided doses for 2 weeks; may increase by 1.2mg/kg per day at 1–2 week intervals; usual maintenance 5–15mg/kg per day; max 400mg/day in 2 divided doses. Patients <30kg: may need higher (≤50%) maintenance dose.

Also:

Precautions for LAMICTAL ODT

Discontinue at first sign of rash (unless clearly not drug related); avoid rechallenge. Avoid rapid dose increases and exceeding recommended dose (may increase risk of serious rash). History of allergy or rash to other AEDs (may increase frequency of nonserious rash). Reevaluate if fever, rash, or other hypersensitivity reaction occurs; discontinue if hypersensitivity occurs. Impaired cardiac function. Moderate or severe hepatic impairment. Significant renal impairment: consider reduced dose. Suicidal tendencies (monitor). Avoid abrupt cessation; taper over at least 2 weeks if possible. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for LAMICTAL ODT

Lamotrigine levels increased by valproate. Lamotrigine levels decreased by phenytoin, carbamazepine, phenobarbital, primidone, rifampin. Monitor with other anticonvulsants. Lamotrigine levels may be decreased by oral contraceptives and increased when they are stopped (if monotherapy: adjust dose), and may affect hormonal replacement therapy or other hormonal contraceptive efficacy. May potentiate other folate inhibitors (eg, trimethoprim). Valproate may increase risk of serious rash. Increased incidence of dizziness, diplopia, ataxia, blurred vision with carbamazepine. No apparent effect on lithium levels.

Adverse Reactions for LAMICTAL ODT

Adults (adjunctive): dizziness, ataxia, somnolence, headache, diplopia, blurred vision, nausea, vomiting. Adults (monotherapy): vomiting, coordination abnormalities, dyspepsia, nausea, dizziness, rhinitis, anxiety, insomnia, pain, weight loss, chest pain, dysmenorrhea, nystagmus, lymphadenopathy. Children (adjunctive): infection, vomiting, fever, dizziness, GI upset, ataxia, tremor, asthenia, bronchitis, flu syndrome, diplopia. Rare: rash (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or benign), hypersensitivity, multiorgan failure, blood dyscrasias. XR: also, cerebellar coordination/balance disorder, asthenic conditions, vertigo.

How is LAMICTAL ODT supplied?

Tabs 25mg, 100mg—100
150mg, 200mg—60
Chewable Dispersible tabs 2mg—30
5mg, 25mg—100
Starter kit 25mg x 35 tabs—1
25mg x 84 tabs + 100mg x 14 tabs—1
25mg x 42 tabs + 100mg x 7 tabs—1
ODT Maintenance Packs—30
ODT Titration Kit 25mg x 21 tabs + 50mg x 7 tabs—1
50mg x 42 tabs + 100mg x 14 tabs—1
25mg x 14 tabs, 50mg x 14 tabs, 100mg x 7 tabs—1
XR tabs—30
XR Titration Kit 25mg x 21 tabs + 50mg x 7 tabs—1
50mg x 14 tabs + 100mg x 14 tabs + 200mg x 7 tabs—1
25mg x 14 tabs + 50mg x 14 tabs + 100mg x 7 tabs—1

Related Disease:

Epilepsy
Seizure disorders

Related Resources

Lamictal XR approved as add-on therapy for primary generalized tonic-clonic seizures

February 01, 2010

The FDA has approved Lamictal XR (lamotrigine extended-release tablets, from GlaxoSmithKline) as a once daily, add-on therapy for epilepsy in patients ≥13 years of age with primary generalized tonic-clonic seizures.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

FDA accepts NDA for retigabine, a treatment for partial-onset seizures

January 04, 2010

Valeant has announced that the FDA has accepted for review the New Drug Application (NDA) for retigabine, a neuronal potassium channel opener for the adjunctive treatment for adult epilepsy patients with partial-onset seizures.

FDA warns of birth defects with valproate sodium, valproic acid, and divalproex sodium

December 03, 2009

The FDA has notified healthcare professionals and patients about the increased risk of neural tube defects and other major birth defects (eg, craniofacial defects and cardiovascular malformations) in babies exposed to valproate sodium and related products (valproic acid and divalproex sodium) during pregnancy.

Sabril available for infantile spasms and adult epileptic seizures

September 21, 2009

Lundbeck has made available Sabril (vigabatrin) powder for oral solution and tablets for the treatment of infantile spasms and refractory complex partial seizures.